Cellectar Biosciences Inc. (CLRB)
NASDAQ: CLRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLRB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.00M
- EPS (TTM)
- -$2.34
- Dividend yield
- None
- 52-week range
- 0.7596 – 4.70
- Day range
- 0.7596 – 0.90
- Volume / Avg
- 80.36K / 97.96K
- Beta
- —
- Shares outstanding
- 10.04M
52-week range
CLRB stock today
Shares of Cellectar Biosciences (CLRB) finished lower on Nov 20 at $0.797, a drop of 11.50% or $0.1036 per share, versus the S&P 500's 3.70% decline. Shares are 83.0% below their 52-week high of $4.70, set on May 5, 2026 and 4.9% above the 52-week low of $0.7596, near the bottom of the past year's range. CLRB is down 73.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 72.1%.
Cellectar Biosciences has posted a net loss over the last twelve months (EPS of -$2.34), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cellectar Biosciences
Company profileCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. James V. Caruso
- Headquarters
- Florham Park, NJ
- Employees
- 11
- Website
- cellectar.com
Financial highlights
Full financialsCellectar Biosciences reported a net loss of $21.8 million, compared with a loss of $44.6 million a year earlier. Diluted earnings per share came in at -$8.35.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-21.79M | $-44.58M | $-42.77M | $-31.79M | $-24.12M |
| EPS (diluted) | $-8.35 | $-41.89 | $-3.50 | $-4.51 | $-4.35 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$11.50+1342.91%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.46 vs $-0.46
- Surprise
- 0.00%
CLRB news
All CLRB news- Cellectar Biosciences Q3 Loss Widens; Eyes FDA Filing For Iopofosine I-131 In H1 2027NasdaqCLRB, ET
- Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswire
- Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131GlobeNewswire
- Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström MacroglobulinemiaGlobeNewswire
Cellectar Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DAREDare Bioscience Inc. | 0.4074 | -9.87% | $8.01M | vs CLRB |
| PTNPalatin Technologies Inc. | 4.58 | -7.10% | $8.16M | vs CLRB |
| PHIOPhio Pharmaceuticals Corp. | 0.656 | -8.25% | $7.84M | vs CLRB |
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs CLRB |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 1.29 | -9.15% | $8.29M | vs CLRB |
| HINDVyome Holdings Inc. | 1.20 | -17.24% | $8.42M | vs CLRB |
| VTGNVistagen Therapeutics Inc. | 0.1636 | -12.33% | $7.56M | vs CLRB |
| LEXXLexaria Bioscience Corp. | 4.03 | -10.24% | $8.49M | vs CLRB |
Indexes, lists and sector
Cellectar Biosciences stock FAQ
What is Cellectar Biosciences's stock price today?
CLRB last traded at $0.797 as of Nov 20, 4:00 PM EST, down 11.50% on the day. Prices are delayed at least 15 minutes.
Does Cellectar Biosciences pay a dividend?
No. Cellectar Biosciences does not currently pay a regular cash dividend.
Who is Cellectar Biosciences's CEO?
Mr. James V. Caruso is the chief executive officer of Cellectar Biosciences Inc., which has about 11 employees.
Has CLRB ever split its stock?
Yes. The most recent CLRB stock split was a 1-for-30 split on Jun 24, 2025, one of 6 splits on record.
What is the CLRB 52-week high?
The 52-week high for CLRB is $4.70 and the 52-week low is $0.7596. The stock is currently 83.0% below its high.